Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AMLCourtney D. DiNardo, Hagop M. Kantarjian, Jessica K. Altman et al.|New England Journal of Medicine|2018Cited by 1.4k
Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experienceArmon Azizi, Tian Yi Zhang, Asiri Ediriwickrema et al.|Leukemia & lymphoma/Leukemia and lymphoma|2020Cited by 29